Tildrakizumab 200 mg. Is double dosing really a window of opportunity? Carlos Llamas-Segura, Marta Cebolla-Verdugo, Ricardo Ruiz-Villaverde

Mid-term Safety and Efficacy of Upadacitinib in Adolescents With Moderate-to-severe Atopic Dermatitis: A Real-life 34-Patient Multicenter Trial F.J. Melgosa-Ramos, A. Vicente Villa, I. Betlloch Mas, S. Santos-Alarcón

Long-Term Real-World Persistence of Guselkumab in Patients With Moderate-to-Severe Psoriasis J. Borrás-Blasco, R. Alcala, A. Valcuende-Rosique, S. Cornejo